Onconetix to present Proclarix clinical data at EAU congress; study of 800+ patients

Onconetix, Inc.

Abstract accepted for 2025 European Association of Urology congress (March 21-24, Madrid).
Presentation titled 'Clinical Performance of Proclarix in Ruling Out Clinically Insignificant or No Prostate Cancer.'
Study includes >800 patients from Lillebaelt Hospital, University Hospital of Southern Denmark.
Proclarix is a biomarker-based blood test; CEO notes potential to reduce biopsies.
No financial terms disclosed; presentation scheduled March 23.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.